Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants

Vaccines are considered one of the greatest medical achievements in the battle against infectious diseases. However, the intractability of various diseases such as hepatitis C, HIV/AIDS, malaria, tuberculosis, and cancer poses persistent hurdles given that traditional vaccine-development methods hav...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2015-08, Vol.3 (3), p.620-637
Main Authors: Lebel, Marie-Ève, Chartrand, Karine, Leclerc, Denis, Lamarre, Alain
Format: Article
Language:English
Subjects:
adjuvant
immune response
Infectious diseases
Life Sciences
Malaria
Nanoparticles
Plant pathology
production methods
recombinant plant virus
Review
vaccine
Vaccines
Vector-borne diseases
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccines are considered one of the greatest medical achievements in the battle against infectious diseases. However, the intractability of various diseases such as hepatitis C, HIV/AIDS, malaria, tuberculosis, and cancer poses persistent hurdles given that traditional vaccine-development methods have proven to be ineffective; as such, these challenges have driven the emergence of novel vaccine design approaches. In this regard, much effort has been put into the development of new safe adjuvants and vaccine platforms. Of particular interest, the utilization of plant virus-like nanoparticles and recombinant plant viruses has gained increasing significance as an effective tool in the development of novel vaccines against infectious diseases and cancer. The present review summarizes recent advances in the use of plant viruses as nanoparticle-based vaccines and adjuvants and their mechanism of action. Harnessing plant-virus immunogenic properties will enable the design of novel, safe, and efficacious prophylactic and therapeutic vaccines against disease.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines3030620